GNH USA

Europe — EMA

Mytolac (Lanreotide)

GNH USA supplies Mytolac (Lanreotide), a somatostatin analog for acromegaly and gastroenteropancreatic neuroendocrine tumors.

Lanreotide

Request sourcing

1
Pack/s

What is Lanreotide?

Lanreotide, the active ingredient in Mytolac, is a somatostatin analog presented as a subcutaneous formulation for injection use. It is employed to control excess growth hormone in acromegaly and to inhibit hormone secretion and tumor growth in gastroenteropancreatic neuroendocrine tumors.

GNH USA supplies Mytolac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved product documentation for global distribution. It offers reliable logistics and supports clinical teams with technical assistance.

What is Lanreotide used for?

Mytolac, a somatostatin analog, is used in endocrine and neuroendocrine disease pathways to suppress hormone secretion.

- Acromegaly: reduces excess growth hormone levels and normalizes insulin‑like growth factor‑1. - Gastroenteropancreatic neuroendocrine tumors: slows tumor progression and controls hormone‑related symptoms. - Carcinoid syndrome: alleviates flushing, diarrhea and abdominal pain by inhibiting serotonin release.

What are the side effects of Lanreotide?

The most frequently reported reactions to Mytolac are related to its injection route and hormonal modulation.

Common Side Effects: - Injection site pain or erythema - Diarrhea - Nausea - Headache

Serious or Rare Side Effects: - Gallbladder disease or gallstones - Acute pancreatitis - Severe hypersensitivity reactions (anaphylaxis)

What precautions apply to Lanreotide?

When prescribing Mytolac, clinicians should consider several safety measures to minimise risks. - Monitor blood glucose: patients may develop hyperglycemia or worsening diabetes. - Assess gallbladder status: prolonged therapy can promote gallstone formation. - Watch for signs of pancreatitis: discontinue if severe abdominal pain or elevated enzymes occur. - Evaluate for hypersensitivity: avoid in individuals with known allergy to lanreotide or other somatostatin analogues. - Adjust in renal or hepatic impairment: use caution and consider dose modification in severe dysfunction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Lanreotide interact with?

Lanreotide may alter the activity of other medicines, requiring clinical attention.

Major Interactions (Avoid): - Concomitant use with other somatostatin analogues (e.g., octreotide) may cause excessive hormonal suppression. - Insulin or oral hypoglycemic agents: lanreotide can reduce insulin requirements, risking hypoglycemia. - Cytochrome P450 substrates metabolised by CYP3A4: potential altered plasma levels.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs) and antipsychotics: possible additive effects on glucose metabolism. - Anticoagulants such as warfarin: monitor INR as hormonal changes may affect coagulation. - Thyroid hormone replacement: assess thyroid function tests periodically.

Frequently asked questions

What conditions is Mytolac used to treat?+
Mytolac is indicated for the treatment of acromegaly, a condition caused by excess growth hormone, and for gastroenteropancreatic neuroendocrine tumors where it helps control tumor growth and hormone‑related symptoms. It is also used to manage carcinoid syndrome symptoms such as flushing and diarrhea.
How does lanreotide work in the body?+
Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors, mainly subtypes 2 and 5. This binding blocks adenylate cyclase, lowers cyclic AMP, and suppresses the release of growth hormone, insulin‑like growth factor‑1, and various gastrointestinal hormones, thereby reducing tumor activity and hormone‑driven effects.
What determines the dosing regimen for Mytolac?+
The dose and frequency of Mytolac are individualized by the prescribing clinician based on the specific indication, disease severity, patient response, and any relevant comorbidities. The prescriber will decide the appropriate regimen and may adjust it over time according to clinical monitoring.
Is Mytolac safe to use during pregnancy or breastfeeding?+
Safety data for lanreotide in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.
How do I order Mytolac from GNH USA?+
To request Mytolac, submit an enquiry on the product page at gnh-usa.com with the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.
How does Mytolac compare with other somatostatin analogues such as octreotide?+
Both lanreotide and octreotide belong to the somatostatin analogue class and share similar mechanisms. Lanreotide typically has a longer half‑life, allowing for less frequent dosing (often every 4 weeks) compared with octreotide, which may require daily or twice‑daily injections. Efficacy in controlling hormone levels is comparable, but the choice depends on patient preference, tolerability and clinical judgment.
What are the recommended storage conditions for Mytolac?+
Mytolac should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours and return it to refrigeration promptly.
How is Mytolac administered to patients?+
Mytolac is given as a subcutaneous injection, usually into the abdomen or thigh. The healthcare professional prepares the dose using aseptic technique, selects an appropriate injection site, and administers the medication at a 45‑degree angle. Patients should be instructed on proper site rotation and disposal of used needles according to local regulations.
What are the most serious risks associated with Mytolac?+
Serious adverse events, although uncommon, include gallbladder disease or gallstone formation, acute pancreatitis, and severe hypersensitivity reactions such as anaphylaxis. Patients should be monitored for abdominal pain, jaundice, or signs of allergic reaction, and the medication should be discontinued promptly if any of these events occur.
Who should not use Mytolac?+
Mytolac is contraindicated in individuals with a known hypersensitivity to lanreotide or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease. The prescriber should evaluate each patient’s medical history before initiating therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Lanreotide
Route
Subcutaneous Use
Manufacturer
Amdipharm Limited
Origin
EU

Related products

Ipstyl

Ipstyl

Lanreotide

Ipsen S.P.A.
EU
Ipstyl Autogel

Ipstyl Autogel

Lanreotide

Institut Produits Synthèse (Ipsen) Ab
EU
Ipstyl Autogel

Ipstyl Autogel

Lanreotide

Institut Produits Synthèse (Ipsen) Ab
EU
Lanrenet

Lanrenet

Lanreotide

Mylan S.P.A.
EU